{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:15:31Z","timestamp":1774062931087,"version":"3.50.1"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1445-3","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T13:01:14Z","timestamp":1508850074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?"],"prefix":"10.1186","volume":"19","author":[{"given":"Vasco C.","family":"Rom\u00e3o","sequence":"first","affiliation":[]},{"given":"Edward M.","family":"Vital","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Eurico","family":"Fonseca","sequence":"additional","affiliation":[]},{"given":"Maya H.","family":"Buch","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"1445_CR1","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","volume":"69","author":"JL Nam","year":"2010","unstructured":"Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69:976\u201386.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR2","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1093\/rheumatology\/keq250","volume":"49","author":"JAB Nies van","year":"2010","unstructured":"van Nies JAB, de Jong Z, van der Helm-van Mil AHM, Knevel R, Le Cessie S, Huizinga TWJ. Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology. 2010;49:2210\u20136.","journal-title":"Rheumatology."},{"key":"1445_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0119683","volume":"10","author":"JT Joensuu","year":"2015","unstructured":"Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordstr\u00f6m D, Blom M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015;10:1\u201327.","journal-title":"PLoS One."},{"key":"1445_CR4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/ar4593","volume":"16","author":"GS Firestein","year":"2014","unstructured":"Firestein GS. The disease formerly known as rheumatoid arthritis. Arthritis Res Ther. 2014;16:114.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/14737159.2015.969244","volume":"15","author":"DS Gibson","year":"2015","unstructured":"Gibson DS, Bustard MJ, McGeough CM, Murray HA, Crockard MA, McDowell A, et al. Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. Expert Rev Mol Diagn. 2015;15:219\u201334.","journal-title":"Expert Rev Mol Diagn."},{"key":"1445_CR6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrrheum.2014.16","volume":"10","author":"D Plant","year":"2014","unstructured":"Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol. 2014;10:329\u201337.","journal-title":"Nat Rev Rheumatol."},{"key":"1445_CR7","first-page":"1","volume":"16","author":"G Dennis Jr","year":"2014","unstructured":"Dennis Jr G, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014;16:1\u201318.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.berh.2014.10.024","volume":"28","author":"MJ Townsend","year":"2014","unstructured":"Townsend MJ. Molecular and cellular heterogeneity in the Rheumatoid Arthritis synovium: Clinical correlates of synovitis. Best Pract Res Clin Rheumatol. 2014;28:539\u201349.","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"1445_CR9","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","volume":"45","author":"KL Hyrich","year":"2006","unstructured":"Hyrich KL, Watson KD, Silman AJ, Symmons DPM, Register TBB. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45:1558\u201365.","journal-title":"Rheumatology (Oxford)"},{"key":"1445_CR10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/rheumatology\/ken002","volume":"47","author":"LE Kristensen","year":"2008","unstructured":"Kristensen LE, Kapetanovic MC, G\u00fclfe A, S\u00f6derlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47:495\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"1445_CR11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","volume":"9","author":"PA Schouwenburg van","year":"2013","unstructured":"van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:164\u201372.","journal-title":"Nat Rev Rheumatol."},{"key":"1445_CR12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.27758","volume":"63","author":"S Saevarsdottir","year":"2011","unstructured":"Saevarsdottir S, Wedr\u00e9n S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011;63:26\u201336.","journal-title":"Arthritis Rheum"},{"key":"1445_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03009742.2011.599073","volume":"41","author":"MK S\u00f6derlin","year":"2012","unstructured":"S\u00f6derlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012;41:1\u20139.","journal-title":"Scand J Rheumatol."},{"key":"1445_CR14","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/rheumatology\/kes184","volume":"51","author":"H Canh\u00e3o","year":"2012","unstructured":"Canh\u00e3o H, Rodrigues AM, Mour\u00e3o AF, Martins F, Santos MJ, Canas-Silva J, et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford). 2012;51:2020\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"1445_CR15","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","volume":"45","author":"KL Hyrich","year":"2006","unstructured":"Hyrich KL, Watson KD, Silman AJ, Symmons DPM, British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45:1558\u201365.","journal-title":"Rheumatology (Oxford)"},{"key":"1445_CR16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12891-016-1192-7","volume":"17","author":"DF McWilliams","year":"2016","unstructured":"McWilliams DF, Walsh DA. Factors predicting pain and early discontinuation of tumour necrosis factor-\u03b1-inhibitors in people with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. BMC Musculoskelet Disord. 2016;17:337.","journal-title":"BMC Musculoskelet Disord."},{"key":"1445_CR17","first-page":"1670","volume":"34","author":"L Mancarella","year":"2007","unstructured":"Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol. 2007;34:1670\u20133.","journal-title":"J Rheumatol."},{"key":"1445_CR18","doi-asserted-by":"crossref","unstructured":"Da\u00efen CI, Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm. 2014;2014:386148, 11 pages.","DOI":"10.1155\/2014\/386148"},{"key":"1445_CR19","first-page":"1","volume":"11","author":"SC Nair","year":"2016","unstructured":"Nair SC, Welsing PMJ, Choi IYK, Roth J, Holzinger D, Bijlsma JWJ, et al. A personalized approach to biological therapy using prediction of clinical response based on MRP8\/14 serum complex levels in rheumatoid arthritis patients. PLoS One. 2016;11:1\u201312.","journal-title":"PLoS One."},{"key":"1445_CR20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","volume":"72","author":"JD Isaacs","year":"2012","unstructured":"Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2012;72:329\u201336.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, D\u00f6rner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909\u201320.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR22","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","volume":"70","author":"K Chatzidionysiou","year":"2011","unstructured":"Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575\u201380.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semarthrit.2012.11.007","volume":"43","author":"RJ Maneiro","year":"2013","unstructured":"Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum. 2013;43:9\u201317.","journal-title":"Semin Arthritis Rheum."},{"key":"1445_CR24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ard.2007.084715","volume":"68","author":"C Potter","year":"2009","unstructured":"Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DPM, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68:69\u201374.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR25","doi-asserted-by":"crossref","unstructured":"Lv Q, Yin Y, Li X, Shan G, Wu X, Liang D, et al. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNF a agent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoS One. 2014;9:e89442.","DOI":"10.1371\/journal.pone.0089442"},{"key":"1445_CR26","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.39595","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canh\u00e3o H, et al. Brief Report: Association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European Registry Analysis. Arthritis Rheumatol. 2016;68:1346\u201352.","journal-title":"Arthritis Rheumatol."},{"key":"1445_CR27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3109\/s10165-010-0409-0","volume":"21","author":"S-Y Kawashiri","year":"2011","unstructured":"Kawashiri S-Y, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24\u00a0weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol. 2011;21:370\u20134.","journal-title":"Mod Rheumatol."},{"key":"1445_CR28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/rheumatology\/ket301","volume":"53","author":"Y-M Pers","year":"2014","unstructured":"Pers Y-M, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology (Oxford). 2014;53:76\u201384.","journal-title":"Rheumatology (Oxford)"},{"key":"1445_CR29","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/annrheumdis-2015-207784","volume":"75","author":"S Kubo","year":"2016","unstructured":"Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, et al. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Ann Rheum Dis. 2016;75:1321\u20137.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR30","doi-asserted-by":"crossref","unstructured":"Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, et al. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Mod Rheumatol. 2017;27:217\u201326.","DOI":"10.1080\/14397595.2016.1206507"},{"key":"1445_CR31","doi-asserted-by":"crossref","unstructured":"Inciarte-Mundo J, Ramirez J, Hern\u00e1ndez MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther. 2016;18:160.","DOI":"10.1186\/s13075-016-1032-z"},{"key":"1445_CR32","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3899\/jrheum.140628","volume":"42","author":"M Abildtrup","year":"2015","unstructured":"Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol. 2015;42:760\u201370.","journal-title":"J Rheumatol."},{"key":"1445_CR33","first-page":"2239","volume":"54","author":"J Inciarte-Mundo","year":"2015","unstructured":"Inciarte-Mundo J, Ruiz-Esquide V, Hernandez MV, Canete JD, Cabrera-Villalba SR, Ramirez J, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatol (United Kingdom). 2015;54:2239\u201343.","journal-title":"Rheumatol (United Kingdom)"},{"key":"1445_CR34","first-page":"1","volume":"74","author":"IY Choi","year":"2015","unstructured":"Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts C a, Foell D, et al. MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:1\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1445_CR35","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3819","volume":"14","author":"HG Raterman","year":"2012","unstructured":"Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012;14:R95.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR36","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1002\/art.27702","volume":"62","author":"RM Thurlings","year":"2010","unstructured":"Thurlings RM, Boumans M, Tekstra J, Van Roon JA, Vos K, Van Westing DM, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010;62:3607\u201314.","journal-title":"Arthritis Rheum."},{"key":"1445_CR37","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1136\/annrheumdis-2011-201115","volume":"71","author":"VE Hogan","year":"2012","unstructured":"Hogan VE, Holweg CTJ, Choy DF, Kummerfeld SK, Hackney JA, Teng YKO, et al. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab. Ann Rheum Dis. 2012;71:1888\u201394.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/keu299","volume":"54","author":"HL Wright","year":"2014","unstructured":"Wright HL, Thomas HB, Moots RJ, Edwards SW. Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. Rheumatology (Oxford). 2014;54:188\u201393.","journal-title":"Rheumatology (Oxford)"},{"key":"1445_CR39","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/art.27226","volume":"62","author":"CP Mavragani","year":"2010","unstructured":"Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta\/alfa ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly hispanic cohort. Arthritis Rheum. 2010;62:392\u2013401.","journal-title":"Arthritis Rheum."},{"key":"1445_CR40","doi-asserted-by":"crossref","unstructured":"Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alfa monoclonal antibody, infliximab. Rheumatology (Oxford). 2008;47:780\u20138.","DOI":"10.1093\/rheumatology\/ken083"},{"key":"1445_CR41","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/ar2912","volume":"12","author":"LG Baarsen van","year":"2010","unstructured":"van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther. 2010;12:R11.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR42","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/art.38400","volume":"66","author":"Y Sanayama","year":"2014","unstructured":"Sanayama Y, Ikeda K, Saito Y, Kagami S-I, Yamagata M, Furuta S, et al. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheumatol (Hoboken, NJ). 2014;66:1421\u201331.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"Suppl 1","key":"1445_CR43","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar2886","volume":"12","author":"MK Crow","year":"2010","unstructured":"Crow MK. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther. 2010;12 Suppl 1:S5.","journal-title":"Arthritis Res Ther"},{"key":"1445_CR44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1089\/hum.2006.17.985","volume":"17","author":"J Adriaansen","year":"2006","unstructured":"Adriaansen J, Kuhlman RR, Van Holten J, Kaynor C, Vervoordeldonk MJBM, Tak DPP. Intraarticular interferon-\u03b2 gene therapy ameliorates adjuvant arthritis in rats. Hum Gene Ther. 2006;17:985\u201396.","journal-title":"Hum Gene Ther."},{"key":"1445_CR45","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1186\/ar1165","volume":"6","author":"J Holten van","year":"2004","unstructured":"van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJM, Plater-Zyberk C, Vervoordeldonk MJ, et al. Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther. 2004;6:R239\u201349.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR46","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1002\/art.21496","volume":"52","author":"AP Treschow","year":"2005","unstructured":"Treschow AP, Teige I, Nandakumar KS, Holmdahl R, Issazadeh-Navikas S. Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice. Arthritis Rheum. 2005;52:3739\u201348.","journal-title":"Arthritis Rheum."},{"key":"1445_CR47","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1136\/ard.2005.040477","volume":"64","author":"J Holten van","year":"2005","unstructured":"van Holten J. Expression of interferon in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis. 2005;64:1780\u20132.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/1529-0131(200002)43:2<270::AID-ANR5>3.0.CO;2-H","volume":"43","author":"TJM Smeets","year":"2000","unstructured":"Smeets TJM, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, et al. The effects of interferon-beta treatment on synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43:270\u20134.","journal-title":"Arthritis Rheum."},{"key":"1445_CR49","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.2741\/1475","volume":"9","author":"PP Tak","year":"2004","unstructured":"Tak PP. IFN-beta in rheumatoid arthritis. Front Biosci. 2004;9:3242\u20137.","journal-title":"Front Biosci."},{"key":"1445_CR50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/bmm.15.18","volume":"9","author":"J Oliver","year":"2015","unstructured":"Oliver J, Plant D, Webster AP, Barton A. Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis. Biomark Med. 2015;9:499\u2013512.","journal-title":"Biomark Med."},{"key":"1445_CR51","first-page":"1","volume":"16","author":"A Montes Marquez","year":"2014","unstructured":"Montes Marquez A, Ferreiro-Iglesias A, Davila-Fajardo C, Pascual-Salcedo D, Perez-Pampin E, Moreno-Ramos M, et al. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. Arthritis Res Ther. 2014;16:1\u20137.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.30130","volume":"63","author":"D Plant","year":"2011","unstructured":"Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG, et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 2011;63:645\u201353.","journal-title":"Arthritis Rheum."},{"key":"1445_CR53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/FPC.0b013e3283544043","volume":"22","author":"SB Krintel","year":"2012","unstructured":"Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L, Benayed R, et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNF\u03b1 inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics. 2012;22:577\u201389.","journal-title":"Pharmacogenet Genomics."},{"key":"1445_CR54","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2217\/pgs.16.16","volume":"17","author":"SL Smith","year":"2016","unstructured":"Smith SL, Plant D, Lee XH, Massey J, Hyrich K, Morgan AW, et al. Previously reported PDE3A\u2013SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics. 2016;17:715\u201320.","journal-title":"Pharmacogenomics."},{"key":"1445_CR55","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/pgs.13.60","volume":"14","author":"I Acosta-Colman","year":"2013","unstructured":"Acosta-Colman I, Palau N, Tornero J, Fern\u00e1ndez-Nebro A, Blanco F, Gonz\u00e1lez-Alvaro I, et al. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics. 2013;14:727\u201334.","journal-title":"Pharmacogenomics."},{"key":"1445_CR56","doi-asserted-by":"crossref","unstructured":"Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013;9:e1003394.","DOI":"10.1371\/journal.pgen.1003394"},{"key":"1445_CR57","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/art.27457","volume":"62","author":"J Cui","year":"2010","unstructured":"Cui J, Saevarsdottir S, Thomson B, Padyukov L, Van Der Helm-van Mil AHM, Nititham J, et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor \u03b1 therapy. Arthritis Rheum. 2010;62:1849\u201361.","journal-title":"Arthritis Rheum."},{"key":"1445_CR58","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/art.33381","volume":"64","author":"D Plant","year":"2012","unstructured":"Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, et al. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum. 2012;64:665\u201370.","journal-title":"Arthritis Rheum."},{"key":"1445_CR59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/tpj.2015.29","volume":"16","author":"A Ferreiro-Iglesias","year":"2016","unstructured":"Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Ca\u00f1ete JD, Raya E, Magro-Checa C, et al. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. Pharmacogenomics J. 2016;16:137\u201340.","journal-title":"Pharmacogenomics J."},{"key":"1445_CR60","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10753-012-9544-4","volume":"36","author":"DA Pappas","year":"2013","unstructured":"Pappas DA, Oh C, Plenge RM, Kremer JM, Greenberg JD. Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis. Inflammation. 2013;36:279\u201384.","journal-title":"Inflammation."},{"key":"1445_CR61","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1038\/ncomms12460","volume":"7","author":"SK Sieberts","year":"2016","unstructured":"Sieberts SK, Zhu F, Garc\u00eda-Garc\u00eda J, Stahl E, Pratap A, Pandey G, et al. Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun. 2016;7:12460.","journal-title":"Nat Commun."},{"key":"1445_CR62","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1136\/annrheumdis-2012-202743","volume":"72","author":"SL Smith","year":"2013","unstructured":"Smith SL, Plant D, Eyre S, Barton A. The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis. Ann Rheum Dis. 2013;72:1118\u201324.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/tpj.2013.48","volume":"14","author":"a N Burska","year":"2014","unstructured":"Burska a N, Roget K, Blits M, Soto Gomez L, van de Loo F, Hazelwood LD, et al. Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics J. 2014;14:93\u2013106.","journal-title":"Pharmacogenomics J"},{"key":"1445_CR64","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/annrheumdis-2013-204603","volume":"74","author":"S Kelly","year":"2013","unstructured":"Kelly S, Humby F, Filer A, Ng N, Di Cicco M, Hands RE, et al. Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients. Ann Rheum Dis. 2013;74:611\u20137.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR65","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/ar4074","volume":"14","author":"K Klein","year":"2012","unstructured":"Klein K, Ospelt C, Gay S. Epigenetic contributions in the development of rheumatoid arthritis. Arthritis Res Ther. 2012;14:227.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR66","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/BOR.0b013e32835d8385","volume":"25","author":"M Ammari","year":"2013","unstructured":"Ammari M, Jorgensen C, Apparailly F. Impact of microRNAs on the understanding and treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2013;25:225\u201333.","journal-title":"Curr Opin Rheumatol."},{"key":"1445_CR67","first-page":"1","volume":"17","author":"C Castro-Villegas","year":"2011","unstructured":"Castro-Villegas C, P\u00e9rez-S\u00e1nchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Lim\u00f3n P, et al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNF\u03b1. Arthritis Res Ther. 2011;17:1\u201315.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR68","doi-asserted-by":"crossref","unstructured":"Cuppen B v, Rossato M, Fritsch-Stork R, Concepcion A, Schenk Y, Bijlsma J, et al. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis? Arthritis Res Ther. 2016;18:189.","DOI":"10.1186\/s13075-016-1085-z"},{"key":"1445_CR69","doi-asserted-by":"crossref","unstructured":"Krintel SB, Dehlendorff C, Hetland ML, H\u00f8rslev-Petersen K, Andersen KK, Junker P, et al. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. Pharmacogenomics J. 2016;16:141\u20136.","DOI":"10.1038\/tpj.2015.30"},{"key":"1445_CR70","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4555","volume":"16","author":"G Dennis","year":"2014","unstructured":"Dennis G, Holweg CT, Kummerfeld SK, Choy DF, Setiadi A, Hackney JA, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014;16:R90.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR71","first-page":"620","volume":"34","author":"B Bresnihan","year":"2007","unstructured":"Bresnihan B, Gerlag DM, Rooney T, Smeets TJM, Wijbrandts CA, Boyle D, et al. Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol. 2007;34:620\u20132.","journal-title":"J Rheumatol."},{"key":"1445_CR72","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/ard.2007.081950","volume":"67","author":"TC Pouw Kraan van der","year":"2008","unstructured":"van der Pouw Kraan TC, Wijbrandts C a, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, et al. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis. 2008;67:563\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1445_CR73","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2007.080440","volume":"67","author":"C a Wijbrandts","year":"2008","unstructured":"Wijbrandts C a, Dijkgraaf MGW, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis. 2008;67:1139\u201344.","journal-title":"Ann Rheum Dis"},{"key":"1445_CR74","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar2678","volume":"11","author":"V Badot","year":"2009","unstructured":"Badot V, Galant C, Nzeusseu Toukap A, Theate I, Maudoux A-L, Van den Eynde BJ, et al. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R57.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR75","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/ard.2008.089284","volume":"68","author":"JD Ca\u00f1ete","year":"2009","unstructured":"Ca\u00f1ete JD, Celis R, Moll C, Izquierdo E, Marsal S, Sanmart\u00ed R, et al. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:751\u20136.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR76","doi-asserted-by":"crossref","unstructured":"Wright HL, Bucknall RC, Moots RJ, Edwards SW. Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Rheumatology (Oxford). 2012;51:451\u20139.","DOI":"10.1093\/rheumatology\/ker338"},{"key":"1445_CR77","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/art.24913","volume":"60","author":"R Klaasen","year":"2009","unstructured":"Klaasen R, Thurlings RM, Wijbrandts CA, Van Kuijk AW, Baeten D, Gerlag DM, et al. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum. 2009;60:3217\u201324.","journal-title":"Arthritis Rheum."},{"key":"1445_CR78","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.27415","volume":"62","author":"LGM Baarsen Van","year":"2010","unstructured":"Van Baarsen LGM, Wijbrandts CA, Timmer TCG, Van Der Pouw KTCTM, Tak PP, Verweij CL. Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. Arthritis Rheum. 2010;62:1602\u20137.","journal-title":"Arthritis Rheum."},{"key":"1445_CR79","first-page":"2158","volume":"34","author":"A Pachot","year":"2007","unstructured":"Pachot A, Arnaud B, Marrote H, Cazalis M-A, Diasparra J, Gouraud A, et al. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. J Rheumatol. 2007;34:2158\u201361.","journal-title":"J Rheumatol."},{"key":"1445_CR80","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2249.2008.03691.x","volume":"153","author":"S Fabre","year":"2008","unstructured":"Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol. 2008;153:188\u201395.","journal-title":"Clin Exp Immunol."},{"key":"1445_CR81","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/ar3431","volume":"13","author":"D-Y Chen","year":"2011","unstructured":"Chen D-Y, Chen Y-M, Chen H-H, Hsieh C-W, Lin C-C, Lan J-L. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-\u03b1 therapy. Arthritis Res Ther. 2011;13:R126.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR82","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/ar1465","volume":"7","author":"H Marotte","year":"2005","unstructured":"Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther. 2005;7:R149\u201355.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR83","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/kes094","volume":"51","author":"K Kayakabe","year":"2012","unstructured":"Kayakabe K, Kuroiwa T, Sakurai N, Ikeuchi H, Kadiombo AT, Sakairi T, et al. Interleukin-1\u03b2 measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis. Rheumatology (Oxford). 2012;51:1639\u201343.","journal-title":"Rheumatology (Oxford)"},{"key":"1445_CR84","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12967-015-0620-z","volume":"13","author":"U Meusch","year":"2015","unstructured":"Meusch U, Krasselt M, Rossol M, Baerwald C, Klingner M, Wagner U. In vitro response pattern of monocytes after tmTNF reverse signaling predicts response to anti-TNF therapy in rheumatoid arthritis. J Transl Med. 2015;13:256.","journal-title":"J Transl Med."},{"key":"1445_CR85","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","volume":"71","author":"S Alzabin","year":"2012","unstructured":"Alzabin S, Abraham SM, Taher TE, Palfreeman a, Hull D, McNamee K, et al. Incomplete response of inflammatory arthritis to TNF blockade is associated with the Th17 pathway. Ann Rheum Dis. 2012;71:1741\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1445_CR86","first-page":"1465","volume":"34","author":"S Visvanathan","year":"2007","unstructured":"Visvanathan S, Marini JC, Smolen JS, St. Clair EW, Pritchard C, Shergy W, et al. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol. 2007;34:1465\u201374.","journal-title":"J Rheumatol."},{"key":"1445_CR87","doi-asserted-by":"crossref","unstructured":"Lequerr\u00e9 T, Jouen F, Brazier M, Clayssens S, Klemmer N, M\u00e9nard JF, et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford). 2007;46:446\u201353.","DOI":"10.1093\/rheumatology\/kel262"},{"key":"1445_CR88","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar3188","volume":"12","author":"S Visvanathan","year":"2010","unstructured":"Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, et al. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther. 2010;12:R211.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR89","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s10067-006-0520-y","volume":"26","author":"G Morozzi","year":"2007","unstructured":"Morozzi G, Fabbroni M, Bellisai F, Cucini S, Simpatico A, Galeazzi M. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol. 2007;26:1335\u20138.","journal-title":"Clin Rheumatol."},{"key":"1445_CR90","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1136\/ard.2007.071910","volume":"66","author":"I Gonz\u00e1lez-Alvaro","year":"2007","unstructured":"Gonz\u00e1lez-Alvaro I, Ortiz AM, Tomero EG, Balsa A, Orte J, Laffon A, et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis. 2007;66:1675\u20138.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR91","doi-asserted-by":"crossref","first-page":"e0163087","DOI":"10.1371\/journal.pone.0163087","volume":"11","author":"BVJ Cuppen","year":"2016","unstructured":"Cuppen BVJ, Fu J, van Wietmarschen HA, Harms AC, Koval S, Marijnissen ACA, et al. Exploring the inflammatory metabolomic profile to predict response to TNF-\u03b1 inhibitors in rheumatoid arthritis. PLoS One. 2016;11:e0163087.","journal-title":"PLoS One."},{"key":"1445_CR92","first-page":"1","volume":"10","author":"R Priori","year":"2015","unstructured":"Priori R, Casadei L, Valerio M, Scrivo R, Valesini G, Manetti C. 1H-NMR-based metabolomic study for identifying serum profiles associated with the response to etanercept in patients with rheumatoid arthritis. PLoS One. 2015;10:1\u201314.","journal-title":"PLoS One."},{"key":"1445_CR93","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/art.37921","volume":"65","author":"SR Kapoor","year":"2013","unstructured":"Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD, et al. Metabolic profiling predicts response to anti-tumor necrosis factor-alfa therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65:1448\u201356.","journal-title":"Arthritis Rheum."},{"key":"1445_CR94","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/art.30233","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Lo\u00ebt X, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63:933\u20138.","journal-title":"Arthritis Rheum."},{"key":"1445_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0040362","volume":"7","author":"G Ferraccioli","year":"2012","unstructured":"Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, Gremese E, Ravagnani V, Benucci M, et al. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: Clues for the pathogenesis. PLoS One. 2012;7:1\u20137.","journal-title":"PLoS One."},{"key":"1445_CR96","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/art.38023","volume":"65","author":"J Sellam","year":"2013","unstructured":"Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, et al. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65:2253\u201361.","journal-title":"Arthritis Rheum."},{"key":"1445_CR97","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1002\/art.22967","volume":"56","author":"YKO Teng","year":"2007","unstructured":"Teng YKO, Levarht EWN, Hashemi M, Bajema IM, Toes REM, Huizinga TWJ, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum. 2007;56:3909\u201318.","journal-title":"Arthritis Rheum."},{"key":"1445_CR98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-016-1091-1","volume":"18","author":"MH Stradner","year":"2016","unstructured":"Stradner MH, Dejaco C, Brickmann K, Graninger WB, Brezinschek HP. A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study. Arthritis Res Ther. 2016;18:1\u20138.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR99","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/art.27359","volume":"62","author":"EM Vital","year":"2010","unstructured":"Vital EM, Dass S, Rawstron AC, Buch MH, Go\u00ebb V, Henshaw K, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum. 2010;62:1273\u20139.","journal-title":"Arthritis Rheum."},{"key":"1445_CR100","doi-asserted-by":"crossref","first-page":"R161","DOI":"10.1186\/ar3901","volume":"14","author":"H-P Brezinschek","year":"2012","unstructured":"Brezinschek H-P, Rainer F, Brickmann K, Graninger WB. B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Res Ther. 2012;14:R161.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR101","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1126\/scitranslmed.3002432","volume":"3","author":"K Owczarczyk","year":"2011","unstructured":"Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg CTJ, Dummer W, et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med. 2011;3:iii2\u201325.","journal-title":"Sci Transl Med"},{"key":"1445_CR102","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","volume":"58","author":"S Dass","year":"2008","unstructured":"Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58:2993\u20139.","journal-title":"Arthritis Rheum."},{"key":"1445_CR103","doi-asserted-by":"crossref","unstructured":"Vital EM, Dass S, Buch MH, Rawstron AC, Emery P. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Ann Rheum Dis. 2015;74:1195\u2013201.","DOI":"10.1136\/annrheumdis-2013-204544"},{"key":"1445_CR104","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","volume":"47","author":"F Breedveld","year":"2007","unstructured":"Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol. 2007;47:1119\u201328.","journal-title":"J Clin Pharmacol."},{"key":"1445_CR105","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/ard.2007.074229","volume":"67","author":"A Kavanaugh","year":"2008","unstructured":"Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, et al. Assessment of rituximab\u2019s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis. 2008;67:402\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1445_CR106","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/art.23473","volume":"58","author":"P Roll","year":"2008","unstructured":"Roll P, D\u00f6rner T, Tony H-P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008;58:1566\u201375.","journal-title":"Arthritis Rheum."},{"key":"1445_CR107","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JCW. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613\u201320.","journal-title":"Arthritis Rheum."},{"key":"1445_CR108","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/art.30599","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, et al. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2011;63:3692\u2013701.","journal-title":"Arthritis Rheum."},{"key":"1445_CR109","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2798","volume":"11","author":"M Nakou","year":"2009","unstructured":"Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11:R131.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR110","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1186\/ar2686","volume":"11","author":"B M\u00f6ller","year":"2009","unstructured":"M\u00f6ller B, Aeberli D, Eggli S, Fuhrer M, Vajtai I, V\u00f6gelin E, et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R62.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR111","doi-asserted-by":"crossref","unstructured":"Adlowitz DG, Barnard J, Biear JN, Cistrone C, Owen T, Wang W, et al. Expansion of activated peripheral blood memory B cells in rheumatoid arthritis, impact of B cell depletion therapy, and biomarkers of response. PLoS One. 2015;10:e0128269.","DOI":"10.1371\/journal.pone.0128269"},{"key":"1445_CR112","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12481","volume":"180","author":"AP Trouvin","year":"2015","unstructured":"Trouvin AP, Jacquot S, Grigioni S, Curis E, Dedreux I, Roucheux A, et al. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study. Clin Exp Immunol. 2015;180:11\u20138.","journal-title":"Clin Exp Immunol."},{"key":"1445_CR113","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","volume":"67","author":"RM Thurlings","year":"2008","unstructured":"Thurlings RM, Vos K, Wijbrandts C a, Zwinderman a H, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67:917\u201325.","journal-title":"Ann Rheum Dis"},{"key":"1445_CR114","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","volume":"56","author":"K Vos","year":"2007","unstructured":"Vos K, Thurlings RM, Wijbrandts CA, Van Schaardenburg D, Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:772\u20138.","journal-title":"Arthritis Rheum."},{"key":"1445_CR115","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/ar2497","volume":"10","author":"S Rosengren","year":"2008","unstructured":"Rosengren S, Wei N, Kalunian KC, Zvaifler NJ, Kavanaugh A, Boyle DL. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther. 2008;10:R105.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR116","doi-asserted-by":"crossref","unstructured":"Care MA, Stephenson SJ, Barnes NA, Fan I, Zougman A, El-sherbiny YM, et al. Network analysis identifies proinflammatory plasma cell polarization for secretion of ISG15 in human autoimmunity. J Immunol. 2016;197:1447\u201359.","DOI":"10.4049\/jimmunol.1600624"},{"key":"1445_CR117","unstructured":"R4-RA Clinical Trial. http:\/\/www.r4ra-nihr.whri.qmul.ac.uk\/ ."},{"key":"1445_CR118","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/ard.2010.147199","volume":"70","author":"S Vosslamber","year":"2011","unstructured":"Vosslamber S, Raterman HG, van der Pouw KTCTM, Schreurs MWJ, von Blomberg BME, Nurmohamed MT, et al. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1153\u20139.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR119","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.38671","volume":"66","author":"J Sellam","year":"2014","unstructured":"Sellam J, Marion-Thore S, Dumont F, Jacques S, Garchon HJ, Rouanet S, et al. Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheumatol. 2014;66:2015\u201325.","journal-title":"Arthritis Rheumatol."},{"key":"1445_CR120","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/art.30292","volume":"63","author":"I Gutierrez-Roelens","year":"2011","unstructured":"Gutierrez-Roelens I, Galant C, Theate I, Lories RJ, Durez P, Nzeusseu-Toukap A, et al. Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium. Arthritis Rheum. 2011;63:1246\u201354.","journal-title":"Arthritis Rheum."},{"key":"1445_CR121","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00296-014-3015-1","volume":"34","author":"YH Lee","year":"2014","unstructured":"Lee YH, Bae SC, Song GG. Functional FCGR3A 158\u00a0V\/F and IL-6\u2009\u2212\u2009174 C\/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis. Rheumatol Int. 2014;34:1409\u201315.","journal-title":"Rheumatol Int."},{"key":"1445_CR122","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/kes344","volume":"52","author":"A Ruyssen-Witrand","year":"2013","unstructured":"Ruyssen-Witrand A, Rouanet S, Combe B, Dougados M, Le Lo\u00ebt X, Sibilia J, et al. Association between \u2013871C\u2009>\u2009T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford). 2013;52:636\u201341.","journal-title":"Rheumatology (Oxford)"},{"key":"1445_CR123","doi-asserted-by":"crossref","unstructured":"Duroux-Richard I, Pers YM, Fabre S, Ammari M, Baeten D, Cartron G, et al. Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. Mediators Inflamm. 2014;2014:342524, 9 pages.","DOI":"10.1155\/2014\/342524"},{"key":"1445_CR124","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2249.2008.03804.x","volume":"155","author":"S Fabre","year":"2009","unstructured":"Fabre S, Guisset C, Tatem L, Dossat N, Dupuy AM, Cohen JD, et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol. 2009;155:395\u2013402.","journal-title":"Clin Exp Immunol."},{"issue":"Suppl 1","key":"1445_CR125","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar2416","volume":"10","author":"MH Buch","year":"2008","unstructured":"Buch MH, Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2008;10 Suppl 1:S5.","journal-title":"Arthritis Res Ther"},{"key":"1445_CR126","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/ard.2008.091876","volume":"68 September","author":"MH Buch","year":"2009","unstructured":"Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes L, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis. 2009;68 September:1220\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1445_CR127","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3899\/jrheum.130905","volume":"41","author":"M Scarsi","year":"2014","unstructured":"Scarsi M, Paolini L, Ricotta D, Pedrini A, Piantoni S, Caimi L, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41:666\u201372.","journal-title":"J Rheumatol."},{"key":"1445_CR128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2172-14-34","volume":"14","author":"J Pieper","year":"2013","unstructured":"Pieper J, Herrath J, Raghavan S, Muhammad K, Vollenhoven R, Malmstrom V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 2013;14:34.","journal-title":"BMC Immunol."},{"key":"1445_CR129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/art.38895","volume":"67","author":"S Iwata","year":"2015","unstructured":"Iwata S, Nakayamada S, Fukuyo S, Kubo S, Yunoue N, Wang SP, et al. Activation of syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. Arthritis Rheumatol. 2015;67:63\u201373.","journal-title":"Arthritis Rheumatol."},{"key":"1445_CR130","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/cei.12367","volume":"177","author":"A Picchianti Diamanti","year":"2014","unstructured":"Picchianti Diamanti A, Rosado MM, Scarsella M, Germano V, Giorda E, Cascioli S, et al. Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-alfa agents. Clin Exp Immunol. 2014;177:630\u201340.","journal-title":"Clin Exp Immunol."},{"key":"1445_CR131","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3899\/jrheum.110386","volume":"38","author":"M Scarsi","year":"2011","unstructured":"Scarsi M, Ziglioli T, Airo P. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2105\u201311.","journal-title":"J Rheumatol."},{"key":"1445_CR132","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0531-5565(03)00090-1","volume":"38","author":"CM Weyand","year":"2003","unstructured":"Weyand CM, Fulbright JW, Goronzy JJ. Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol. 2003;38:833\u201341.","journal-title":"Exp Gerontol."},{"key":"1445_CR133","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-016-1052-8","volume":"18","author":"S Nakamura","year":"2016","unstructured":"Nakamura S, Suzuki K, Iijima H, Hata Y, Lim CR, Ishizawa Y, et al. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. Arthritis Res Ther. 2016;18:159.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR134","doi-asserted-by":"crossref","first-page":"229","DOI":"10.59566\/IJBS.2014.10229","volume":"10","author":"M Umemura","year":"2014","unstructured":"Umemura M, Isozaki T, Ishii S, Seki S, Oguro N, Miura Y, et al. Reduction of serum ADAM17 level accompanied with decreased cytokines after abatacept therapy in patients with rheumatoid arthritis. Int J Biomed Sci. 2014;10:229\u201335.","journal-title":"Int J Biomed Sci."},{"key":"1445_CR135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0000000000000071","volume":"21","author":"C Enevold","year":"2014","unstructured":"Enevold C, Baslund B, Linde L, Josephsen NL, Tarp U, Lindegaard H, et al. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics. 2014;21:1\u20135.","journal-title":"Pharmacogenet Genomics."},{"key":"1445_CR136","doi-asserted-by":"crossref","first-page":"e003199","DOI":"10.1136\/bmjopen-2013-003199","volume":"3","author":"J Wang","year":"2013","unstructured":"Wang J, Platt A, Upmanyu R, Germer S, Lei G, Rabe C, et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open. 2013;3:e003199.","journal-title":"BMJ Open."},{"key":"1445_CR137","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/tpj.2012.8","volume":"13","author":"J Wang","year":"2013","unstructured":"Wang J, Bansal a T, Martin M, Germer S, Benayed R, Essioux L, et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J. 2013;13:235\u201341.","journal-title":"Pharmacogenomics J"},{"key":"1445_CR138","doi-asserted-by":"crossref","unstructured":"Maldonado-Montoro M, Ca\u00f1adas-Garre M, Gonz\u00e1lez-Utrilla A, Plaza-Plaza JC, Calleja-Hern\u00e1ndez M\u00c1. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacol Res.\u00a02016;111:264\u201327.","DOI":"10.1016\/j.phrs.2016.06.016"},{"key":"1445_CR139","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3899\/jrheum.110961","volume":"39","author":"B Mesko","year":"2012","unstructured":"Mesko B, Poliska S, Szamosi S, Szekanecz Z, Podani J, Varadi C, et al. Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis. J Rheumatol. 2012;39:916\u201328.","journal-title":"J Rheumatol."},{"key":"1445_CR140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.38202","volume":"66","author":"J Ducreux","year":"2014","unstructured":"Ducreux J, Durez P, Galant C, Toukap AN, Van Den Eynde B, Houssiau FA, et al. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014;66:15\u201323.","journal-title":"Arthritis Rheumatol."},{"key":"1445_CR141","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13075-016-0919-z","volume":"18","author":"A Groof De","year":"2016","unstructured":"De Groof A, Ducreux J, Humby F, Nzeusseu Toukap A, Badot V, Pitzalis C, et al. Higher expression of TNF\u03b1-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy. Arthritis Res Ther. 2016;18:19.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR142","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3899\/jrheum.121389","volume":"40","author":"K Shimamoto","year":"2013","unstructured":"Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013;40:1074\u201381.","journal-title":"J Rheumatol."},{"key":"1445_CR143","first-page":"1","volume":"10","author":"K Uno","year":"2015","unstructured":"Uno K, Yoshizaki K, Iwahashi M, Yamana J, Yamana S, Tanigawa M, et al. Pretreatment prediction of individual rheumatoid arthritis patients\u2019 response to anti-cytokine therapy using serum cytokine\/chemokine\/soluble receptor biomarkers. PLoS One. 2015;10:1\u201315.","journal-title":"PLoS One."},{"key":"1445_CR144","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/annrheumdis-2013-204417","volume":"73","author":"S Das","year":"2014","unstructured":"Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, et al. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann Rheum Dis. 2014;73:909\u201312.","journal-title":"Ann Rheum Dis."},{"key":"1445_CR145","doi-asserted-by":"crossref","unstructured":"Lee SJ, Park W, Park SH, Shim SC, Baek HJ, Yoo DH, et al. Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients. J Immunol Res. 2015;2015:487230, 7 pages.","DOI":"10.1155\/2015\/487230"},{"key":"1445_CR146","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-015-0580-y","volume":"17","author":"Z Mahmood","year":"2015","unstructured":"Mahmood Z, Muhammad K, Schmalzing M, Roll P, D\u00f6rner T, Tony H-P. CD27\u2013IgD\u2013 memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis. Arthritis Res Ther. 2015;17:61.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0526-4","volume":"17","author":"J Kikuchi","year":"2015","unstructured":"Kikuchi J, Hashizume M, Kaneko Y, Yoshimoto K, Nishina N, Takeuchi T. Peripheral blood CD4\u2009+\u2009CD25\u2009+\u2009CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. Arthritis Res Ther. 2015;17:1\u201310.","journal-title":"Arthritis Res Ther."},{"key":"1445_CR148","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341\u201352.","DOI":"10.1016\/S0140-6736(15)61074-1"},{"key":"1445_CR149","first-page":"1","volume":"10","author":"JW Whitaker","year":"2015","unstructured":"Whitaker JW, Boyle DL, Bartok B, Ball ST, Gay S, Wang W, et al. Integrative omics analysis of rheumatoid arthritis identifies non-obvious therapeutic targets. PLoS One. 2015;10:1\u201314.","journal-title":"PLoS One."},{"key":"1445_CR150","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/ar2706","volume":"11","author":"W Hueber","year":"2009","unstructured":"Hueber W, Tomooka BH, Batliwalla F, Li W, Monach P a, Tibshirani RJ, et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R76.","journal-title":"Arthritis Res Ther"},{"key":"1445_CR151","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7150\/thno.12403","volume":"5","author":"A Obry","year":"2015","unstructured":"Obry A, Hardouin J, Lequerr\u00e9 T, Jarnier F, Boyer O, Fardellone P, et al. Identification of 7 proteins in sera of RA patients with potential to predict ETA\/MTX treatment response. Theranostics. 2015;5:1214\u201324.","journal-title":"Theranostics."},{"key":"1445_CR152","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jprot.2012.09.011","volume":"77","author":"I Ortea","year":"2012","unstructured":"Ortea I, Roschitzki B, Ovalles JG, Longo JL, de la Torre I, Gonz\u00e1lez I, et al. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. J Proteomics. 2012;77:372\u201382.","journal-title":"J Proteomics."},{"key":"1445_CR153","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard.2008.093153","volume":"68","author":"C Trocm\u00e9","year":"2009","unstructured":"Trocm\u00e9 C, Marotte H, Baillet a, Pallot-Prades B, Garin J, Grange L, et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1328\u201333.","journal-title":"Ann Rheum Dis"},{"key":"1445_CR154","doi-asserted-by":"crossref","first-page":"e000197","DOI":"10.1136\/rmdopen-2015-000197","volume":"2","author":"K Hambardzumyan","year":"2016","unstructured":"Hambardzumyan K, Bolce RJ, Saevarsdottir S, Forslind K, Wallman JK, Cruickshank SE, et al. Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. RMD Open. 2016;2:e000197.","journal-title":"RMD Open."},{"key":"1445_CR155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0153140","volume":"11","author":"I Ortea","year":"2016","unstructured":"Ortea I, Roschitzki B, L\u00f3pez-Rodr\u00edguez R, Tomero EG, Ovalles JG, L\u00f3pez-Longo J, et al. Independent candidate serum protein biomarkers of response to adalimumab and to infliximab in rheumatoid arthritis: an exploratory study. PLoS One. 2016;11:1\u201313.","journal-title":"PLoS One."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1445-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:10:52Z","timestamp":1719533452000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1445-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1445-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,24]]},"article-number":"239"}}